Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2021-06-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
华邦生命健康股份有限公司关于签署战略合作协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Huabang Life Health Co., Ltd. regarding the signing of a strategic cooperation agreement with Zhejiang Xin'an Chemical Group Co., Ltd. and Beijing Yingtai Jiahe Biotechnology Co., Ltd. It details the cooperation framework, parties involved, and the potential impact on the company. The document is relatively short (3251 characters) and focuses on the announcement of a strategic partnership rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial data, nor is it a report or transcript. It is not a notice of voting results, dividend, or share transactions. The content fits best under a general regulatory announcement category as it informs investors about a material cooperation agreement and associated risks. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-06-09 Chinese
华邦生命健康股份有限公司关于全资子公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary's pharmaceutical product passing a regulatory consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, and potential impact on the company. The document is short (1004 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category.
2021-06-08 Chinese
关于2021年度第一期超短期融资券发行情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance of a short-term financing bond by 华邦生命健康股份有限公司 in 2021. It details the bond issuance amount, registration, approval, and specific terms such as interest rate and issuance date. The content focuses on financing activities and capital raising rather than financial results, management changes, or regulatory filings. The document length is short (957 characters) and it is not a report or a certification but a specific update on capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-05-07 Chinese
关于举行2021年第一季度报告网上说明会的公告
Call Transcript Classification · 85% confidence The document is an announcement about the holding of an online earnings conference call (performance explanation meeting) for the company's 2021 first quarter report. It mentions the date and time of the call, the platform, and invites investors to participate and submit questions. It also states that the full quarterly report has already been published elsewhere. The document does not contain the actual financial data or detailed financial statements but is focused on the event of the earnings call and interaction with investors. Therefore, this document is best classified as a Call Transcript (CT) announcement or related to the earnings call event. However, since it is an announcement of the earnings call and not the transcript itself, and given the options, the closest and most appropriate classification is Call Transcript (CT) as it relates to the earnings call event.
2021-04-28 Chinese
2021年第一季度报告正文
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2021 First Quarter Report" of 华邦生命健康股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, cash flow, asset and liability changes, shareholder information, and risk disclosures. The length is 9613 characters, which is substantial and contains actual financial statements and analysis. The content matches the characteristics of an Interim / Quarterly Report (IR) rather than an announcement or summary. There is no indication that this is an Annual Report (10-K), Earnings Release (ER), or any other category. Therefore, the document is classified as an Interim / Quarterly Report (IR). Q1 2021
2021-04-27 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "华邦生命健康股份有限公司 2021 年第一季度报告全文" which translates to "Huabang Life Health Co., Ltd. 2021 First Quarter Report Full Text." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the first quarter of 2021. The document includes comprehensive financial metrics, shareholder information, risk disclosures, and management statements. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2021
2021-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.